Millendo Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$36,406,000 over the previous period. Total operating expenses were $35,972,000.
Profit Margin
| 2012 | 0 | -13.51M | |
|---|---|---|---|
| 2013 | 0 | -29.04M | |
| 2014 | 0 | -49.52M | |
| 2015 | 277K | -73.21M | -26432.85% |
| 2016 | 653K | -82.26M | -12597.24% |
| 2017 | 295K | -50.97M | -17279.66% |
| 2018 | 0 | -27.19M | |
| 2019 | 0 | -44.56M | |
| 2020 | 0 | -36.40M |
MLND Income Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
Revenue | 0 | 0 | 0 | 295K | 653K | 277K | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 | 790K | 5.40M | 2.24M | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | -495K | -4.74M | -1.97M | 0 | 0 | 0 |
Operating exp. | |||||||||
Research and development | 20.37M | 27.84M | 14.42M | 18.33M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 35.97M | 45.39M | 26.87M | 46.08M | 70.86M | 70.02M | 47.93M | 29.13M | 13.52M |
Operating income | -35.97M | -45.39M | -26.87M | -46.57M | -75.61M | -71.99M | -47.93M | -29.13M | -13.52M |
Other income (expenses), net | -434K | 831K | -303K | -4.33M | -6.44M | -1.14M | -1.58M | 90K | 19K |
Income before tax | -36.40M | -44.56M | -27.17M | -50.90M | -82.05M | -73.14M | -49.52M | -29.04M | -13.51M |
Income tax expense | -434K | -207K | -169K | 67K | 201K | 75K | -1.58M | 90K | 0 |
Net income | -36.40M | -44.56M | -27.19M | -50.97M | -82.26M | -73.21M | -49.52M | -29.04M | -13.51M |
Earnings per share | |||||||||
Basic EPS | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -524.24 |
Diluted EPS | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -524.24 |
| Data source |